Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury.
about
Targeting leukocyte integrins in human diseasesInflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression.Myosin light chain kinase in microvascular endothelial barrier function.ICAM-1 as a molecular target for triple negative breast cancerInnate response to self-antigen significantly exacerbates burn wound depth.A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myelomaCO-releasing molecules (CORM-2)-liberated CO attenuates leukocytes infiltration in the renal tissue of thermally injured mice.Myosin light chain kinase signaling in endothelial barrier dysfunction.A conformational change of C-reactive protein in burn wounds unmasks its proinflammatory properties.Carbon liberated from CO-releasing molecules attenuates leukocyte infiltration in the small intestine of thermally injured mice.Wound healing activity of carbon monoxide liberated from CO-releasing molecule (CO-RM).Toll-Like Receptor Signaling in Burn Wound Healing and Scarring.CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.Therapeutic blockade of CD54 attenuates pulmonary barrier damage in T cell-induced acute lung injury.
P2860
Q28293910-CCEB4E72-2D2E-4653-AD53-B5B7B0E17C5BQ33898626-F2B3A4E8-5759-4CD8-BEF7-24F763851F5BQ33954983-450E5833-7DC9-4B29-A5C6-EA09F9847A09Q34383956-A1E5F275-9330-413E-BC64-B98A19D5442FQ35676741-D311410D-B024-48B1-9AB2-D53F7DD1A654Q36270127-0A05183F-9E16-4561-A878-F103EDCE89D6Q36727192-88FE1FD5-7DEF-4119-8B50-73E832C23378Q37076073-93598CEF-7B3A-4274-BDF4-A11E2654BE45Q38993371-BFFA91D1-9B0C-410D-91A9-7EE5DB42758CQ41962280-D0462380-E0E1-44B2-962A-B48F130B7F58Q42735731-20A41369-D625-4728-8C43-31981C361E12Q45415293-0997B905-C65B-412E-83EA-D3D3709E96C3Q47449809-438F3572-F4E5-4816-A862-84836DE268F4Q47901480-381973D4-7C81-4A26-A4AB-2EEC1B8A2DA1
P2860
Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinical effects of inhibiting ...... partial-thickness burn injury.
@ast
Clinical effects of inhibiting ...... partial-thickness burn injury.
@en
type
label
Clinical effects of inhibiting ...... partial-thickness burn injury.
@ast
Clinical effects of inhibiting ...... partial-thickness burn injury.
@en
prefLabel
Clinical effects of inhibiting ...... partial-thickness burn injury.
@ast
Clinical effects of inhibiting ...... partial-thickness burn injury.
@en
P2093
P1433
P1476
Clinical effects of inhibiting ...... partial-thickness burn injury.
@en
P2093
Arnold Luterman
Cleon W Goodwin
David M Heimbach
David N Herndon
Deborah Burkhart
Jeffrey R Saffle
John Hansborough
John L Hunt
Richard J Kagan
Roger W Yurt
P304
P356
10.1097/01.TA.0000030626.84680.11
P407
P577
2003-05-01T00:00:00Z